This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MGP / Matrix Gla protein · IHC design guide
Design Immunohistochemistry for MGP
Plan MGP staining in paraffin sections using chondrocyte staining in cartilage as a positive reference (HPA tissue IHC). This guide covers fixation consistency, epitope coverage and interpretation of a secreted protein (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MGP Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Secreted; tissue compartment unresolved (UniProt) | |
| Staining pattern | High in chondrocytes; low in breast gland cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet PB9954) | |
| Positive control | Cartilage+1 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Secreted protein may stain beyond producing cells (UniProt) | |
| Regulation | Expression regulation not specified (UniProt) | |
| Isoform / epitope | 2 isoforms; mature chain 20–96; check epitope coverage (UniProt) |
Section 1
Recommended MGP IHC & IF Protocols
The catalog antibody’s IHC-P protocol is paired with three published MGP immunohistochemistry protocols (PMC11178913; PMC11195983; PMC3731399).
| Sample | Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet PB9954) |
| Fixation | Image fixative and duration unreported (datasheet PB9954); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet PB9954); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet PB9954) |
| Primary antibody | Rabbit anti-MGP, 0.5-1μg/ml (datasheet PB9954) |
| Primary incubation | Overnight at 4 °C (datasheet PB9954) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9954) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MGP-positive staining in chondrocytes of cartilage (HPA tissue IHC: High). HPA tissue profile: Expressed in chondrocytes and breast glands. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet: PB9954). The published excerpts do not specify retrieval conditions (PMC11178913; PMC11195983; PMC3731399).
Section 2
What Is the Expected MGP Staining Pattern?
MGP is a secreted protein with no transmembrane segment and associates with the organic matrix of bone and cartilage (UniProt P08493). On IHC paraffin sections, expect the strongest reported staining in cartilage chondrocytes (HPA: High); prostate glandular cells show Medium staining and breast glandular cells Low staining (HPA tissue IHC). HPA rates its tissue staining profile Approved while cautioning that secreted protein and RNA locations may differ (HPA tissue IHC).
| Strong staining associated with cartilage chondrocytes, with possible nearby matrix staining. | This fits the reported High chondrocyte signal (HPA tissue IHC: cartilage). Nearby matrix signal is biologically plausible because MGP is secreted and associates with cartilage matrix (UniProt P08493). HPA does not specify a required intracellular or pericellular staining pattern, so assess the cell and surrounding tissue together. |
| Moderate prostate glandular staining or faint breast glandular staining. | These levels fit the reported Medium prostate and Low breast glandular signals (HPA tissue IHC). Compare each tissue with its own expected level; a weak breast result need not match the intensity of cartilage. Staining intensity alone does not establish which MGP form the antibody detects (UniProt P08493: processing and modified residues). |
| Predominantly nuclear staining, with little signal associated with the expected cells or surrounding tissue. | A nuclear-only pattern is discordant with MGP's Secreted annotation and lack of a transmembrane segment (UniProt P08493). Treat it as possible nonspecific staining and check controls and antibody performance (general IHC practice). Transient intracellular protein during secretion remains possible; the source record does not define a required intracellular compartment. |
| Strong staining in a cell population HPA reports as Not detected, such as adipocytes. | HPA reports MGP as Not detected in adipocytes (HPA tissue IHC: adipose tissue). Check whether staining follows tissue structures or appears across unrelated cells; cross-reactivity or endogenous detection activity are possible explanations (general IHC practice). One discrepant section alone does not identify which explanation applies. |
| Broad, similar chromogen deposition over positive and negative tissue areas. | A uniform pattern obscures the contrast expected between High chondrocytes and HPA Not detected cell populations (HPA tissue IHC). Consider background from detection chemistry, inadequate blocking, or excessive antibody concentration (general IHC practice). Reassess localisation only after controls show that the background is under control. |
💡Expected MGP appearanceCall a section positive when staining is strongest in cartilage chondrocytes (HPA: High), with a secreted or matrix-associated distribution consistent with MGP (UniProt P08493); uniform background or a dominant nuclear-only pattern is suspect (general IHC practice).
| Secretion and processing | MGP has a signal peptide at residues 1–19 and a reported mature chain at 20–96 (UniProt P08493). Interpret cellular staining alongside possible deposited protein; HPA warns that secreted protein and tissue RNA locations may differ (HPA tissue IHC). The supplied record does not establish a required ratio of cellular to matrix staining. |
| Antibody recognition of MGP forms | UniProt lists two isoforms, a propeptide at 97–103, and modified residues including carboxyglutamate and phosphoserine (UniProt P08493). Without an epitope or form-specific validation in the supplied sources, do not infer which processed, modified, or isoform-specific species contributes to the IHC signal. |
| Strength of tissue and antibody evidence | HPA marks the tissue IHC profile Approved and lists antibody HPA013949 as IHC Approved (HPA tissue IHC; HPA antibodies). These labels support use of the reported pattern as a reference; the supplied antibody record does not say IHC Enhanced or document agreement between two independent antibodies. |
| Antigen retrieval in paraffin sections | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. |
| IF/ICC Q&A: Is a subcellular pattern established? | HPA calls MGP Secreted but provides no main ICC-IF location or cell-line images (HPA subcellular). The IHC tissue pattern therefore cannot define an IF punctate, cytoplasmic, or nuclear pattern. Assess IF/ICC localisation in its separate guide; no IF/ICC protocol is supplied here. |
| Situation | Likely cause | Next action |
|---|---|---|
| No staining in a cartilage section expected to be positive. | Chondrocytes are reported High (HPA tissue IHC: cartilage); a blank section could reflect assay performance or the sampled area (general IHC practice). The sources do not identify an MGP-specific fixation failure. | Confirm the section contains chondrocytes, then review the IHC-validated antibody, retrieval, primary incubation, and chromogenic detection with appropriate positive and omission controls (general IHC practice). |
| Prostate glandular cells appear negative while cartilage stains. | HPA reports Medium prostate glandular staining versus High cartilage chondrocyte staining (HPA tissue IHC). A weaker signal may be missed at the chosen detection threshold (general IHC practice). | Review glandular morphology and compare matched runs before changing interpretation; optimise detection against positive and negative controls without treating all tissues as equally intense (general IHC practice). |
| Breast glandular staining is weak or difficult to score. | HPA reports Low staining in breast glandular cells (HPA tissue IHC). Weak signal can be difficult to distinguish from chromogen background (general IHC practice). | Score the glandular cells against local background and control sections; use High cartilage staining as a run-level reference, not as the expected breast intensity (HPA tissue IHC; general IHC practice). |
| Nuclei dominate the stain, including in HPA Not detected cells. | A nuclear-only pattern conflicts with the Secreted annotation (UniProt P08493). Signal in HPA Not detected cells raises concern for nonspecific binding or detection activity (HPA tissue IHC; general IHC practice). | Inspect primary-omission and detection controls, confirm the expected cartilage pattern, and adjust blocking or antibody conditions if background persists (general IHC practice). |
| Diffuse chromogen covers both expected positive and negative areas. | Loss of tissue contrast can result from excessive primary or detection signal, inadequate blocking, or endogenous activity (general IHC practice). HPA's High and Not detected categories provide comparison points (HPA tissue IHC). | Check omission controls, review blocking and detection steps, and adjust staining conditions until morphology and tissue contrast are interpretable (general IHC practice). |
| Protein staining does not follow the tissue RNA enrichment signal. | HPA reports RNA as tissue enriched in blood vessel while its protein IHC profile highlights chondrocytes and breast glands; it warns that secreted protein and RNA locations may differ (HPA tissue IHC). | Interpret the stained section using its protein IHC cell pattern and controls. Do not label the RNA-to-protein mismatch an antibody failure without independent evidence (HPA tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing MGP staining
PB9954 · IHCIHC analysis of MGP using anti-MGP antibody (PB9954). MGP was detected in a paraffin-embedded section of human lung cancer tissue. Heat medi
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000111341-MGP/tissue/cerebral+cortex#imid_20487139
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000111341-MGP/tissue/colon#imid_20486489
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000111341-MGP/tissue/liver#imid_20486506
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000111341-MGP/tissue/kidney#imid_20486507
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MGP IHC & IF
🧪Run cartilage first: chondrocytes should stain (HPA: High in chondrocytes). Use adipose tissue as the negative, with adipocytes expected to show no detected signal (HPA: Not detected in adipocytes); on the cartilage slide, cells without specific staining should show only counterstain or background, while extracellular matrix staining may reflect secreted MGP (UniProt P08493: secreted; associates with cartilage matrix).
Positive control tissue: Cartilage (Chondrocytes, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for MGP; derive a cell-line control from the positive tissue's cell type (Chondrocytes) and confirm it by RNA or western blot first.
Technical controls: Include no-primary (secondary-only) and matched rabbit IgG isotype controls (caption: rabbit anti-MGP primary; standard IHC practice), plus MGP knockout tissue or a validated peptide-block control (standard IHC practice). For cartilage stained with SABC/DAB, quench endogenous peroxidase and assess endogenous biotin background (caption: SABC/DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected PB9954 paraffin-section caption does not state a fixative (PB9954 caption: fixative unreported). That caption uses heat retrieval in EDTA at pH 8.0, but does not establish whether retrieval is required for all specimens (PB9954 caption: heat retrieval). Frozen sections or IF cannot be judged easier from the supplied evidence; extracellular cartilage matrix staining may complicate cell-level scoring because MGP is secreted and associates with cartilage matrix (UniProt P08493: secreted; cartilage matrix association).
HPA tissue IHC evidence for MGP
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — At least one protein variant secreted, tissue location of RNA and protein might differ and correlation is complex.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cartilage | Chondrocytes | High | Protein (IHC) | HPA → |
| Prostate | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Lymphoid tissue | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced MGP IHC Tips
Troubleshoot MGP staining in paraffin sections by checking retrieval, compartment, controls and scoring before interpreting chromogenic signal.
Which retrieval condition should I start with for MGP in paraffin sections?
Use heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections stained with PB9954 (datasheet PB9954). Keep retrieval conditions identical across comparison sections, then check whether signal appears in the expected chondrocyte or extracellular region (standard IHC practice; HPA tissue IHC; UniProt P08493 localisation). The selected tissue image used this EDTA condition before incubation with 1 μg/ml antibody overnight at 4°C (PB9954 tissue-IHC caption). If staining is weak, vary heating duration in a small pilot while monitoring tissue integrity; record each condition alongside a positive-control section (standard IHC practice).
How should I assess whether fixation is affecting MGP staining?
The PB9954 tissue image identifies a paraffin-embedded section, but does not state its fixative; target-specific fixation sensitivity is therefore unknown (PB9954 tissue-IHC caption). Record the fixative and fixation duration for each specimen, and compare sections processed under matched conditions before changing antibody concentration (standard IHC practice). For a pilot, retain the specified EDTA retrieval at pH 8.0 and the caption’s 1 μg/ml primary concentration so the fixation comparison remains interpretable (datasheet PB9954; PB9954 tissue-IHC caption; standard IHC practice). Evaluate morphology and staining together, using a positive-control section in each run to flag processing variation (standard IHC practice).
Where should convincing MGP staining appear in a tissue section?
Interpret MGP as a secreted protein without a transmembrane segment, so inspect extracellular material as well as cells rather than requiring a membrane outline (UniProt P08493 topology and localisation). HPA reports high staining in cartilage chondrocytes and medium staining in prostate glandular cells, which offer cell-level reference patterns (HPA tissue IHC). Compare staining with a counterstained serial section to assign signal to cells or surrounding matrix, especially where boundaries are indistinct (standard IHC practice). A purely nuclear pattern needs independent validation because the supplied localisation is secreted, whereas adjacent extracellular signal can complicate cell attribution (UniProt P08493 localisation; standard IHC practice).
Could processing or modification change which MGP molecules the antibody detects?
Map the antibody’s documented epitope, if available, against MGP’s 1–19 signal peptide, 20–96 mature chain and 97–103 propeptide before interpreting staining (UniProt P08493 processing; standard IHC practice). MGP has 2 annotated isoforms, but the supplied PB9954 caption does not establish which isoform its staining represents (UniProt P08493 isoforms; PB9954 tissue-IHC caption). Gamma-carboxyglutamate and phosphoserine sites are annotated, so an epitope spanning a modified residue could merit a separate specificity check (UniProt P08493 modified residues; standard IHC practice). Compare independent epitope reagents or appropriate competition controls when available, while keeping retrieval and detection conditions matched (standard IHC practice).
How can IF help check the cellular source of an IHC MGP signal?
For a separate IF experiment, multiplex MGP with a marker that identifies the expected cell population, such as a chondrocyte marker in cartilage, and inspect signal outside the marked cells too (HPA tissue IHC; UniProt P08493 localisation; standard IF practice). Choose fluorophores whose emission is distinguishable from tissue autofluorescence, and include single-stain and no-primary controls when assessing overlap (standard IF practice). Because MGP is secreted and has no transmembrane segment, choose permeabilisation based on the documented epitope and whether intracellular precursor or extracellular protein is being examined (UniProt P08493 topology and processing; standard IF practice). Do not treat the PB9954 chromogenic tissue caption as evidence of IF validation (PB9954 tissue-IHC caption).
How do I separate diffuse MGP staining from chromogenic background?
First compare the stained section with a no-primary control and inspect whether colour follows tissue edges, folds or damaged regions (standard IHC practice). The selected PB9954 image used 10% goat serum blocking, a biotinylated secondary, streptavidin–biotin detection and DAB, so review blocking and detection controls when background rises (PB9954 tissue-IHC caption; standard IHC practice). Include peroxidase blocking and an appropriate endogenous-biotin control when using that detection chemistry; both address general assay background rather than MGP-specific biology (standard IHC practice). A diffuse extracellular pattern can be biologically plausible for secreted MGP, but should persist with tissue structure and disappear in the no-primary control (UniProt P08493 localisation; standard IHC practice).
What should I score when MGP appears in cells and matrix? ⚠ ANSWER MARKED FOR VERIFICATION
Define cellular and extracellular compartments before scoring because MGP is secreted and can associate with matrix (UniProt P08493 localisation and function; standard IHC practice). For cellular staining, report the percentage of positive cells and an H-score based on intensity categories; keep the cell population and threshold fixed across sections (standard IHC practice). For extracellular DAB, measure positive area or optical-density signal per mm² of evaluable tissue, excluding folds and necrosis under predefined rules (standard IHC practice). Normalise cell counts to the number of eligible cells and matrix measurements to evaluable tissue area, then report the compartments separately (standard IHC practice).
What findings make an apparent MGP positive result questionable?
A signal confined to nuclei is questionable because the supplied protein localisation is secreted, and a sharp edge-only pattern suggests a section artefact (UniProt P08493 localisation; standard IHC practice). Check whether staining follows intact chondrocytes or surrounding matrix in cartilage, where HPA reports high chondrocyte expression, rather than relying on colour alone (HPA tissue IHC; UniProt P08493 function). Discount staining limited to necrotic regions, folds or the no-primary control, and investigate residual endogenous peroxidase or biotin signal when using DAB with streptavidin–biotin detection (standard IHC practice; PB9954 tissue-IHC caption). Confirm a disputed pattern on an independently processed section with matched retrieval before assigning biological meaning (standard IHC practice).
Boster reagents
Best MGP / Matrix Gla protein IHC Antibodies
The IHC-validated anti-MGP antibody has real chromogenic IHC data from paraffin-embedded human lung cancer tissue (PB9954 image caption).
Real IHC data
Anti-MGP Antibody ®
Cat # PB9954
PB9954 is the sole card and is listed for human IHC (catalog applications/reactivity). Its figure shows MGP staining in a paraffin-embedded human lung cancer section with DAB detection (PB9954 image caption).
Which to pick: Choose PB9954 for human paraffin-section IHC: it is a rabbit antibody listed for human IHC, and its figure shows staining after EDTA retrieval at pH 8.0 (catalog host/applications/reactivity; PB9954 image caption). No listed SKU supports an IF/ICC or cross-species recommendation: PB9954 lists human IHC and WB, with no IF figure or nonhuman reactivity (catalog applications/reactivity; PB9954 image inventory). The figure caption reports paraffin embedding but does not identify the fixative, so fixation is unconfirmed (PB9954 image caption). The selected PB9954 tissue-IHC caption documents paraffin sections, but does not specify the fixative (selected-SKU IHC image PB9954).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P08493 (MGP_HUMAN, Matrix Gla protein).
- Human Protein Atlas. MGP tissue IHC expression (reliability: Approved).
- Human Protein Atlas. MGP subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. MGP antibody validation summary (1 antibodies).
- Thrombospondin 2, matrix Gla protein and digital analysis identified distinct fibroblast populations in fibrostenosing Crohn's disease. Scientific reports 2024 — PMC11178913.
- Dietary intervention rescues a bone porosity phenotype in a murine model of Neurofibromatosis Type 1 (NF1). PloS one 2024 — PMC11195983.
- Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. The Journal of experimental medicine 2002 — PMC2194039.
- Calcium oxalate nephrolithiasis and expression of matrix GLA protein in the kidneys. World journal of urology 2014 — PMC3731399.
- PubMed PMID:2394711 — UniProt-cited evidence.
- PubMed PMID:3387234 — UniProt-cited evidence.
- PubMed PMID:2216462 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MGP (Matrix Gla protein). Expected localisation Secreted; tissue compartment unresolved (UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet PB9954). Validated IHC antibody: PB9954 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cartilage (Chondrocytes); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet PB9954); 2. Fixation: Image fixative and duration unreported (datasheet PB9954); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet PB9954); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet PB9954); 8. Primary antibody: Rabbit anti-MGP, 0.5-1μg/ml (datasheet PB9954); 9. Primary incubation: Overnight at 4 °C (datasheet PB9954). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Secreted protein may stain beyond producing cells (UniProt); Isoform / epitope: 2 isoforms; mature chain 20–96; check epitope coverage (UniProt); Regulation: Expression regulation not specified (UniProt). Evidence: UniProt P08493, HPA tissue IHC · Approved, HPA ICC-IF · Secreted, Datasheet PB9954, PMC11178913, PMC11195983. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MGP/immunohistochemistry-ihc-guide.